Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies
Tianhong Li, Hsing‐Jien Kung, Philip C. Mack, et al.
Journal of Clinical Oncology (2013) Vol. 31, Iss. 8, pp. 1039-1049
Open Access | Times Cited: 481

Showing 1-25 of 481 citing articles:

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Răzvan Cristescu, Jeeyun Lee, Michael Nebozhyn, et al.
Nature Medicine (2015) Vol. 21, Iss. 5, pp. 449-456
Closed Access | Times Cited: 1835
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, et al.
Journal of the National Comprehensive Cancer Network (2017) Vol. 15, Iss. 4, pp. 504-535
Open Access | Times Cited: 1213
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon, Tudor‐Eliade Ciuleanu, Óscar Arrieta, et al.
The Lancet (2014) Vol. 384, Iss. 9944, pp. 665-673
Closed Access | Times Cited: 1191
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 5, pp. 497-530
Closed Access | Times Cited: 1051
Toward personalized treatment approaches for non-small-cell lung cancer
Meina Wang, Roy S. Herbst, Chris Boshoff
Nature Medicine (2021) Vol. 27, Iss. 8, pp. 1345-1356
Closed Access | Times Cited: 693
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan, Lili Huang, Jianhua Chen, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 602
The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics
Ting‐Yuan David Cheng, Susanna Cramb, Peter D. Baade, et al.
Journal of Thoracic Oncology (2016) Vol. 11, Iss. 10, pp. 1653-1671
Open Access | Times Cited: 563
Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
Adrian G. Sacher, Cloud P. Paweletz, Suzanne E. Dahlberg, et al.
JAMA Oncology (2016) Vol. 2, Iss. 8, pp. 1014-1014
Open Access | Times Cited: 541
Non–Small Cell Lung Cancer, Version 6.2015
David S. Ettinger, Douglas E. Wood, Wallace Akerley, et al.
Journal of the National Comprehensive Cancer Network (2015) Vol. 13, Iss. 5, pp. 515-524
Closed Access | Times Cited: 466
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
Jean‐Yves Douillard, Gyula Ostoros, Manuel Cobo, et al.
Journal of Thoracic Oncology (2014) Vol. 9, Iss. 9, pp. 1345-1353
Open Access | Times Cited: 433
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhe Zhang, Li Zhou, Na Xie, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 429
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
David S. Ettinger, Douglas E. Wood, Wallace Akerley, et al.
Journal of the National Comprehensive Cancer Network (2016) Vol. 14, Iss. 3, pp. 255-264
Open Access | Times Cited: 388
Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning
Shuo Wang, Jingyun Shi, Zhaoxiang Ye, et al.
European Respiratory Journal (2019) Vol. 53, Iss. 3, pp. 1800986-1800986
Open Access | Times Cited: 366
Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer
Emmanuel Rios Velazquez, Chintan Parmar, Ying Liu, et al.
Cancer Research (2017) Vol. 77, Iss. 14, pp. 3922-3930
Open Access | Times Cited: 349
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer
Feifei Cheng, Li Su, Cheng Qian
Oncotarget (2016) Vol. 7, Iss. 30, pp. 48832-48841
Open Access | Times Cited: 321
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Gonzalo Recondo, Francesco Facchinetti, Ken A. Olaussen, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 11, pp. 694-708
Closed Access | Times Cited: 297
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments
Jonathan A. Ledermann, S. Canevari, Tate Thigpen
Annals of Oncology (2015) Vol. 26, Iss. 10, pp. 2034-2043
Closed Access | Times Cited: 290
Scientific Advances in Lung Cancer 2015
Anne S. Tsao, Giorgio V. Scagliotti, Paul A. Bunn, et al.
Journal of Thoracic Oncology (2016) Vol. 11, Iss. 5, pp. 613-638
Open Access | Times Cited: 270
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Robert J. Motzer, Eric Jonasch, M. Dror Michaelson, et al.
Journal of the National Comprehensive Cancer Network (2019) Vol. 17, Iss. 11, pp. 1278-1285
Open Access | Times Cited: 269
Advances in pathogenesis and therapeutic strategies for osteoporosis
Shasha Song, Yuanyuan Guo, Yuehua Yang, et al.
Pharmacology & Therapeutics (2022) Vol. 237, pp. 108168-108168
Closed Access | Times Cited: 268
Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Alexander Drilon, Lu Wang, Maria E. Arcila, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 16, pp. 3631-3639
Open Access | Times Cited: 259
Biomarkers for personalized oncology: recent advances and future challenges
Madhu Kalia
Metabolism (2014) Vol. 64, Iss. 3, pp. S16-S21
Closed Access | Times Cited: 248
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, et al.
PubMed (2015) Vol. 4, Iss. 2, pp. 156-64
Closed Access | Times Cited: 244
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
Cloud P. Paweletz, Adrian G. Sacher, Chris K. Raymond, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 4, pp. 915-922
Open Access | Times Cited: 230
FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer
Dickran Kazandjian, Gideon M. Blumenthal, Weishi Yuan, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 6, pp. 1307-1312
Closed Access | Times Cited: 202
Page 1 - Next Page

Scroll to top